BioSpace News Archive

Eagle Pharmaceuticals, Inc. announced that the Company has resubmitted its New Drug Application for RYANODEX® for the treatment of exertional heat stroke, in addition to body cooling, to the U.S. Food and Drug Administration.

Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018

AMAG Pharmaceuticals, Inc. announced the initiation of a leadership transition, the decision to divest Intrarosa and Vyleesi and financial updates

CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, maintains a leading presence at the American Society of Transplant Surgeons Winter Symposium January 9-12, 2020 in Miami, Florida.

Replimune Group Inc. announced the evolution of the responsibilities within its executive leadership team, reflecting the progress the Company has made into later stage clinical development and as it prepares for future commercialization.

Applied Genetic Technologies Corporation reported positive interim six-month data from its ongoing Phase 1/2 clinical program in X-linked retinitis pigmentosa.

The investment arm of Debiopharm, a private, Swiss corporate fund specialized in Smart Data and Digital Health, leads the Series A

Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that ROTH Capital Partners will conduct a Key Opinion Leader call for their institutional clients.

Healios K.K. Japan’s leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative therapies announces that its Chairman and Chief Executive Officer, Hardy TS Kagimoto, MD, will provide a strategic overview and company update at the 38th Annual J.P. Morgan Healthcare Conference.

Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia ossificans progressiva (FOP)